Skip to main content
Download PDF

Correction: The molecular subtyping and precision medicine in triple-negative breast cancer--- based on Fudan TNBC classification

Cancer Cell International volume 25, Article number: 171 (2025) Cite this article

The Original Article was published on 30 March 2024

Correction to: Cancer Cell International (2024) 24:120

https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12935-024-03261-0

In this article [1], the author would like to update the second affiliation as below for funding purpose.

Incorrect affiliation:

Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Ningbo University, Ningbo, China.

Correct affiliation:

Department of Radiotherapy and Chemotherapy, Ningbo First Hospital Zhejiang University Ningbo Hospital, Ningbo, China.

References

  1. Weng L, Zhou J, Guo S, Xu N, Ma R. The molecular subtyping and precision medicine in triple-negative breast cancer—based on Fudan TNBC classification. Cancer Cell Int. 2024;24(1):120.

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China

    Lijuan Weng & Nong Xu

  2. Department of Radiotherapy and Chemotherapy, Ningbo First Hospital Zhejiang University Ningbo Hospital, Ningbo, China

    Lijuan Weng, Jianliang Zhou, Shenchao Guo & Ruishuang Ma

Authors
  1. Lijuan Weng
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Jianliang Zhou
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Shenchao Guo
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Nong Xu
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Ruishuang Ma
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding authors

Correspondence to Nong Xu or Ruishuang Ma.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weng, L., Zhou, J., Guo, S. et al. Correction: The molecular subtyping and precision medicine in triple-negative breast cancer--- based on Fudan TNBC classification. Cancer Cell Int 25, 171 (2025). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12935-025-03799-7

Download citation

  • Accepted:

  • Published:

  • DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12935-025-03799-7

Cancer Cell International

ISSN: 1475-2867

Contact us